Clincosm LogoSign in Get a demo

Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Gait Parameters Study

Sponsor
Oregon Health and Science University (Other)
Overall Status
Unknown status
CT.gov ID
NCT01565447
Collaborator
(none)
200
Enrollment
1
Location
108
Duration (Months)
1.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This purpose of this study it to characterize the walking patterns of children diagnosed with Acute Lymphoblastic Leukemia (ALL)and Lymphoblastic Lymphoma (LL) at different times in the treatment protocol and after completion of treatment. Their walking patterns will be compared to children without ALL or LL to see if their walking patterns are different at specific times in their treatment program or up to 10 years after completion of their treatment. The investigators will gather data by observing how the child walks, runs, hops on one foot and climbs stairs and by recording walking patterns on a pressure sensitive mat. The investigators will compare this data to children without ALL and LL.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Cases will be identified and referred by the primary oncologist or by the Childhood Cancer Survivorship team. When a possible subject has been identified they will be contacted via telephone or during a routine clinic visit to determine their interest in the study. Two hundred subjects will be recruited for participation with the goal of 5-10 subjects at each of the 14 times points across the treatment protocol and survivorship. These time points to include: at diagnosis, the start of consolidation therapy, the start of interim maintenance therapy, the start of delayed intensification therapy, Day 29 of delayed intensification therapy, the start of interim maintenance II therapy (if applicable), Day 1 of cycle 1,3,5 of maintenance therapy, end of therapy, and 1, 3, 5, and 10 years off therapy ( +/-1 year).

    Clinical data will be collected from the medical record, roadmaps documenting cancer-directed therapy, direct patient interview and examination by the physical therapist during the study evaluation. Clinical data will include: Date of birth (to calculate age at diagnosis and current age); Gender; Race and Ethnicity; Primary cancer diagnosis; Date of Primary Cancer Diagnosis; Chemotherapeutic agents received (agent name, cumulative dose and date received); Radiation therapy (date received, site radiated, and dose delivered); Any other clinical conditions affecting musculoskeletal performance; Dates of previous PT; Pain score at the time of study participation. Height, weight, shoe size and leg length will be collected at time of study participation.

    Subjects will complete a self report of the PedsQL™ Generic Core Scale and the parents will complete the parental report.

    Observation gait assessment will include hopping on one foot, running and walking 30' and ascending/descending stairs.

    Temporal spatial gait parameters will be recorded on the GaitRite mat

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Other
    Time Perspective:
    Cross-Sectional
    Official Title:
    Temporal and Spatial Gait Parameters of Children Undergoing Treatment for and Surviving Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
    Study Start Date :
    Dec 1, 2011
    Anticipated Primary Completion Date :
    Dec 1, 2020
    Anticipated Study Completion Date :
    Dec 1, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Children with ALL or LL

    Children diagnosed with ALL or LL will be recruited for this study

    Outcome Measures

    Primary Outcome Measures

    1. Temporal and Spatial Gait [At diagnosis, start of consolidation tx, the start of interim maintenance tx, the start of delayed intensification tx, Day 29 of delayed intensification tx, the start of interim maintenance II tx (if applicable), Day 1 of cycle, 1,3,5 of maintenance tx.]

      To characterize temporal and spatial gait parameters of children with ALL/LL at specific time points during their treatment and survivorship using the GAITRite® evaluation system.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    2 Years to 27 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    1. Age 2-27 years of age

    2. Diagnosis of acute lymphoblastic leukemia or lymphoblastic lymphoma

    3. Currently undergoing treatment for ALL or LL or completed treatment for ALL or LL in the last 10 years.

    Exclusion Criteria

    1. Relapsed ALL or LL

    2. Received a stem cell transplant, either autologous or allogeneic

    3. Non ambulatory status prior to diagnosis of acute lymphoblastic leukemia or lymphoblastic lymphoma

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Doernbecher Children Hospital Portland Oregon United States 97239

    Sponsors and Collaborators

    • Oregon Health and Science University

    Investigators

    • Study Director: Susan Lindemulde, MD, MCR, Oregon Health and Science University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nancy Durben, Assistant Professor of Physical Therapy, Oregon Health and Science University
    ClinicalTrials.gov Identifier:
    NCT01565447
    Other Study ID Numbers:
    • OregonHSU
    First Posted:
    Mar 28, 2012
    Last Update Posted:
    Sep 10, 2019
    Last Verified:
    Sep 1, 2019
    Additional relevant MeSH terms:
    Lymphoma
    Leukemia
    Precursor Cell Lymphoblastic Leukemia-Lymphoma
    Leukemia, Lymphoid
    Lymphoma, Non-Hodgkin

    Study Results

    No Results Posted as of Sep 10, 2019